Trial Profile

Immune Memory After Papillomavirus Vaccination (IMAP-I) Study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Human papillomavirus infections
Focus Biomarker; Pharmacodynamics
Acronyms IMAP-1

Most Recent Events

09 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
09 Apr 2012 Planned end date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
10 Jan 2012 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com